Integra lifesciences Sustainability Profile
Integra LifeSciences Holdings Corporation, commonly referred to as Integra, is a prominent player in the medical technology industry, headquartered in the United States. Founded in 1989, the company has established itself as a leader in regenerative medicine and neurosurgery, with a strong presence in North America, Europe, and Asia. Integra's core offerings include advanced wound care products, neurosurgical solutions, and surgical instruments, distinguished by their innovative designs and commitment to improving patient outcomes. The company is particularly noted for its Integra Dermal Regeneration Template, which has revolutionised the treatment of complex wounds. With a robust market position, Integra has achieved significant milestones, including strategic acquisitions that have expanded its product portfolio and global reach. As a trusted partner in healthcare, Integra LifeSciences continues to drive advancements in surgical and regenerative solutions, enhancing the quality of care for patients worldwide.
DitchCarbon Score
How does Integra lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Integra lifesciences's score of 49 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Integra lifesciences's reported carbon emissions
In 2024, Integra LifeSciences reported total carbon emissions of approximately 14555000 kg CO2e for Scope 1, 11944000 kg CO2e for Scope 2, and 96161000 kg CO2e for Scope 3 emissions. This reflects a significant increase in emissions compared to 2023, where Scope 1 emissions were about 8277000 kg CO2e, Scope 2 emissions were approximately 15333000 kg CO2e, and Scope 3 emissions reached about 156706000 kg CO2e. In 2022, the company recorded Scope 1 emissions of approximately 13215000 kg CO2e, Scope 2 emissions of about 16210000 kg CO2e, and Scope 3 emissions of approximately 158981000 kg CO2e. The data indicates a fluctuating trend in emissions over the years, with a notable peak in Scope 3 emissions in 2023. Integra LifeSciences has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The emissions data is sourced directly from Integra LifeSciences Holdings Corporation, with no cascaded data from a parent or related organization. The company continues to monitor its carbon footprint as part of its commitment to sustainability, although specific reduction strategies have not been disclosed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 13,902,000 | 00,000,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 18,609,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is Integra lifesciences's Industry?
How Carbon Intensive is Integra lifesciences's Location?
Integra lifesciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Integra lifesciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
